Comparative Pharmacology
Head-to-head clinical analysis: LIDOCATON versus XARACOLL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIDOCATON versus XARACOLL.
LIDOCATON vs XARACOLL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lidocaine is a class IB antiarrhythmic agent that blocks voltage-gated sodium channels, inhibiting the inward sodium current, thereby stabilizing cardiac membranes, decreasing automaticity, and increasing the fibrillation threshold. It also acts as a local anesthetic by reversibly blocking nerve impulse propagation.
XARACOLL (bupivacaine and meloxicam) is a fixed-dose combination product for local analgesia. Bupivacaine is an amide local anesthetic that blocks sodium ion channels, inhibiting nerve impulse conduction. Meloxicam is an NSAID that inhibits cyclooxygenase (COX) isoforms, reducing prostaglandin synthesis.
Lidocaine: Initial IV bolus 1-1.5 mg/kg, then IV infusion 1-4 mg/min. Adjust for arrhythmia suppression.
Adults: Single dose of 1.3 g (two microspheres) applied intraoperatively directly to the subcutaneous tissue before wound closure.
None Documented
None Documented
Terminal half-life 1.5–2 hours (adults); prolonged in heart failure (up to 4–6 hours) or hepatic impairment (up to 8 hours).
Terminal elimination half-life is approximately 2-4 hours; clinical context: methadone-like opioid, prolonged half-life in elderly, renal impairment, or hepatic impairment; requires monitoring for accumulation.
Renal: ~90% as metabolites (major metabolite 4-hydroxyxylidine) and ~10% unchanged. Biliary/fecal: <5%.
Primarily hepatic metabolism followed by renal excretion of metabolites; approximately 70-80% eliminated in urine (metabolites), <15% unchanged in feces via biliary excretion.
Category C
Category C
Local Anesthetic
Local Anesthetic